Anfibatide Phase Ib-IIa Clinical Trial

Inclusion Criteria: 1. Aged 18-70 years; 2. Laboratory tests show increase of the markers of myocardial damage (CK-MB,CTnI), or reduction after increase, with at least one values exceeding the 99th percentile of the upper limit of the reference value; 3. Ischemia symptoms (ischemic chest pain lasts for over 15 minutes, little release after taking nitroglycerin sublingually) or a new myocardial ischemia on electrocardiogram(ECG), i.e. a new ST-T variation (a new or transient depression of ST segment by over 0.1mV, or T-wave inversion≥0.2mV); 4. Patients receive PCI after coronary angiography; 5. Patients, or their family or guardian give signed informed consent forms. Exclusion Criteria: 1. Patients with severe unstable hemodynamics who should receive urgent PCI; 2. Patients with untreated hypertension (SBP\>180 mmHg or DBP \>110mmHg) and hypotension shock (SBP\<90mmHg/80mmHg for over 30min); 3. Investigator considers patients need to use GPIIb/IIIa receptor antagonists during the study period; 4. After coronary angiography, the number of stenosed vessels \>2；lesions in left main branch, severe calcification and artery graft lesions; 5. Patients with heart function in decompensatory phase (Killip grade 3-4) or cardiac shock; 6. Patients with malignant arrhythmia, e.g. the third-degree atrioventricular block, ventricular tachycardia or fibrillation ventricular; 7. Patients with severe hepatic or renal dysfunction, with serum aspartate transaminase(AST) and alanine transaminase (ALT) exceeding 1.5 times the upper limit of reference values, creatinine clearance \<30ml/min or serum creatinine ≥200μmol/L or 2.5mg/dl; 8. Patients who have received PCI in the past six months; 9. Patients who have received coronary artery bypass grafting (CABG) previously; 10. Patients who have received invasive operation in the past 3 months; 11. Patients who have suffered from ischemic stroke or transient ischemic attack (TIA) in the past 6 months, or patients with past history of hemorrhagic stroke; 12. Patients who need a long-term treatment of oral anticoagulants (such as warfarin); 13. Patients with active peptic ulcer, or other diseases of hemorrhagic tendency; 14. Patients with disease of coagulation disorder; 15. Hematology test shows platelet count \<100,000mm3,or hemoglobin\<100g/L; 16. Women in pregnant or lactation period, or women of child-bearing age do not take efficient contraception measures; 17. Patients with an allergic constitution; 18. Patients who is participating in other clinical trials; 19. Patients who do not give a signed informed consent forms; 20. Patients who are not suitable to enroll in the trial according to the investigator's judgement.